{"id":4638,"date":"2026-06-09T13:06:16","date_gmt":"2026-06-09T13:06:16","guid":{"rendered":"https:\/\/bangbizarre.com\/index.php\/2026\/06\/09\/daily-slimming-pill-helps-patients-lose-body-weight\/"},"modified":"2026-06-09T13:06:18","modified_gmt":"2026-06-09T13:06:18","slug":"daily-slimming-pill-helps-patients-lose-body-weight","status":"publish","type":"post","link":"https:\/\/bangbizarre.com\/index.php\/2026\/06\/09\/daily-slimming-pill-helps-patients-lose-body-weight\/","title":{"rendered":"Daily slimming pill helps patients lose body weight"},"content":{"rendered":"<p><b>2026-06-09 13:06:16<\/b><br \/>\n<BR>A daily weight-loss pill could become a major rival to blockbuster slimming jabs after helping patients lose 11 per cent of their body weight in just six months.<BR><br \/>\nDrug giant AstraZeneca revealed promising trial results for elecoglipron, an experimental tablet that also improved blood sugar levels in patients.<BR><br \/>\nResearchers found the once-a-day pill helped users lose an average of 10.5 per cent of their body weight after 26 weeks.<BR><br \/>\nThe findings come from two studies involving more than 700 people.<BR><br \/>\nExperts say the results suggest elecoglipron could challenge upcoming weight-loss pills being developed by the makers of Wegovy and Mounjaro.<BR><br \/>\nThe treatment works in a similar way to popular GLP-1 injections, suppressing hunger signals in the brain and gut to reduce overeating.<BR><br \/>\nUnlike some rival treatments, elecoglipron can be taken at any time of day, with or without food.<BR><br \/>\nResearchers also found the pill successfully lowered blood sugar into the target treatment range.<BR><br \/>\nCambridge University diabetes expert Dr Marie Spreckley, who was not involved in the research, welcomed the results.<BR><br \/>\nShe said: \u201cThese findings show substantial improvements in both weight and glycaemic control.<BR><br \/>\n\u201cOne potentially important feature of elecoglipron is that it is taken orally without food or fluid restrictions.<BR><br \/>\n\u201cThis could be convenient for some patients.\u201d<BR><br \/>\nThe results compare favourably with other oral weight-loss drugs currently in development.<BR><br \/>\nA semaglutide pill from Novo Nordisk, the manufacturer of Wegovy, achieved a 13.6 per cent reduction in body weight over 64 weeks.<BR><br \/>\nMeanwhile, Eli Lilly&#8217;s orforglipron, developed by the company behind Mounjaro, delivered an 11.2 per cent reduction over 72 weeks.<BR><br \/>\nThe latest findings suggest elecoglipron may offer similar benefits in a considerably shorter period.<BR><br \/>\nDemand for weight-loss treatments has surged in recent years, with millions of people turning to medications to tackle obesity and improve their health.<BR><br \/>\nWhile further testing is still needed before approval, the early results have raised hopes that convenient daily tablets could soon join injections as a powerful weapon in the battle against obesity and type 2 diabetes.<br \/>\n<br \/><a href=\"https:\/\/bangbizarre.com\/\" target=\"_blank\"> Visit Bang Bizarre (main website) <\/a><br \/>\n<br \/><script src=\"https:\/\/geo.dailymotion.com\/player\/xtbac.js\" data-video=\"\"><\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>2026-06-09 13:06:16 A daily weight-loss pill could become a major rival to blockbuster slimming jabs after helping patients lose 11 per cent of their body weight in just six months.&hellip;<\/p>\n","protected":false},"author":1,"featured_media":4639,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-4638","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bizarre"],"_links":{"self":[{"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/posts\/4638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/comments?post=4638"}],"version-history":[{"count":1,"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/posts\/4638\/revisions"}],"predecessor-version":[{"id":4640,"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/posts\/4638\/revisions\/4640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/media\/4639"}],"wp:attachment":[{"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/media?parent=4638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/categories?post=4638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bangbizarre.com\/index.php\/wp-json\/wp\/v2\/tags?post=4638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}